Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1141 ARTÍCULOS , VIENDO DEL 211 AL 225

Amylin: what might be its role in Alzheimer's disease and how could this affect therapy?

Despa F, Decarli C.

Expert Rev Proteomics. 2013 Oct;10(5):403-5. doi: 10.1586/14789450.2013.841549.

Antidepressants for neuro-regeneration: from depression to Alzheimer's disease

Kim HJ, Kim W, Kong SY.

Arch Pharm Res. 2013 Nov;36(11):1279-90. doi: 10.1007/s12272-013-0238-8. Epub 2013 Oct 16.

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronenberger C, Togo K, Ishibashi T, Bednar MM, Kupiec JW, Binneman B.

Int J Clin Pharmacol Ther. 2013 Dec;51(12):911-23. doi: 10.5414/CP201816.

Preserving cognition, quality of life, physical health and functional ability in Alzheimer's disease: the effect of physical exercise (ADEX trial): rationale and design

Hoffmann K, Frederiksen KS, Sobol NA, Beyer N, Vogel A, Simonsen AH, Johannsen P, Lolk A, Terkelsen O, Cotman CW, Hasselbalch SG, Waldemar G.

Neuroepidemiology. 2013;41(3-4):198-207. doi: 10.1159/000354632. Epub 2013 Oct 15.

Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid-β

Wang ZC, Zhao J, Li S.

Neurosci Bull. 2013 Dec;29(6):752-60. doi: 10.1007/s12264-013-1383-2. Epub 2013 Oct 17.

Current and emerging therapies for Alzheimer's disease

Nygaard HB.

Clin Ther. 2013 Oct;35(10):1480-9. doi: 10.1016/j.clinthera.2013.09.009.

Cross-talk of membrane lipids and Alzheimer-related proteins

Walter J, van Echten-Deckert G.

Mol Neurodegener. 2013 Oct 22;8:34. doi: 10.1186/1750-1326-8-34.

Immunotherapy for Alzheimer's disease: hoops and hurdles

Lemere CA.

Mol Neurodegener. 2013 Oct 22;8:36. doi: 10.1186/1750-1326-8-36.

Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection

Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D.

Eur J Med Chem. 2013;70:165-88. doi: 10.1016/j.ejmech.2013.09.050. Epub 2013 Oct 6.

Association between illness progression measures and total cost in Alzheimer's disease

Lacey LA, Niecko T, Leibman C, Liu E, Grundman M; ELN-AIP-901 Investigator Group.

J Nutr Health Aging. 2013 Sep;17(9):745-50. doi: 10.1007/s12603-013-0368-1.

[Towards a vaccine against Alzheimer's?]

Dodel R.

Drug Res (Stuttg). 2013 Nov;63 Suppl 1:S18-20. doi: 10.1055/s-0033-1346715. Epub 2013 Nov 15.

Repression of Alzheimer's beta-secretase

Liao FF, Wang R, Park EA.

Aging (Albany NY). 2013 Nov;5(11):789-90. doi: 10.18632/aging.100612.

Top 20 articles cited from Alzheimer's & Dementia since 2008

Khachaturian AS.

Alzheimers Dement. 2013 Nov;9(6):619-21. doi: 10.1016/j.jalz.2013.10.001.

Ingestion of Chlorella reduced the oxidation of erythrocyte membrane lipids in senior Japanese subjects

Miyazawa T, Nakagawa K, Takekoshi H, Higuchi O, Kato S, Kondo M, Kimura F, Miyazawa T.

J Oleo Sci. 2013;62(11):873-81. doi: 10.5650/jos.62.873.

Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease

Chen Y, Sun J, Peng S, Liao H, Zhang Y, Lehmann J.

Arch Pharm (Weinheim). 2013 Dec;346(12):865-71. doi: 10.1002/ardp.201300074. Epub 2013 Nov 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias